Association between retinal vein occlusion, axial length and vitreous chamber depth measured by optical low coherence reflectometry.

BACKGROUND: Results of ocular biometric measurements in retinal vein occlusion (RVO) eyes are still inconclusive and controversial. The aim of this study was to evaluate the association between ocular axial length (AL), vitreous chamber depth (VCD) and both central (CRVO) and branch retinal vein occlusions (BRVO) using optical low coherence reflectometry (OLCR). METHODS: Both eyes of 37 patients with unilateral CRVO (mean age: 66 +/- 14 years, male:female - 21:16) and 46 patients with unilateral BRVO (mean age: 63 +/- 12 years, male:female - 24:22) were enrolled in this study. The control group consisted of randomly selected single eyes of 67 age and gender matched volunteers without the presence or history of RVO (mean age: 64 +/- 14 years, male:female - 34:33). Optical biometry was performed by OLCR biometer (LenStar LS 900). Average keratometry readings, central corneal thickness (CCT), anterior chamber depth (ACD), lens thickness (LT), AL and VCD of eyes with RVO were compared with those of fellow eyes using paired t-tests and with those of control eyes using independent t-tests. RESULTS: Mean CCT, ACD and LT, average keratometry readings of affected RVO eyes, unaffected fellow eyes and control eyes was not statistically different in either groups. In eyes with CRVO mean AL and VCD of affected eyes were significantly shorter than those of control eyes (p < 0.001, p < 0.05), mean difference in AL and VCD between the affected and control eyes was 0.56 +/- 0.15 mm and 0.45 +/- 0.19 mm, respectively. In eyes with BRVO, mean AL of the affected eyes was significantly shorter with a mean difference of 0.57 +/- 0.15 mm (p < 0.001) and the VCD was significantly shorter with a mean difference of 0.61 +/- 0.15 mm (p < 0.001) comparing with the control eyes. CONCLUSION: Shorter AL and VCD might be a potential anatomical predisposing factor for development either of CRVO or BRVO

Inferior Spear-like Lens Opacity as A Sign of Keratoconus

Purpose: To report 21 cases of typical inferior feather-shape lens opacity associated with keratoconus. Methods: In this cross-sectional study, we evaluated the association of keratoconus with inferior feather-shape lens opacity in refractive surgery candidates. Visual acuity, demographic, refractive, and topographic characteristics of 26 eyes of 21 patients with inferior feather-shape lens opacity were evaluated in detail. Pedigree analysis was also performed to assess possible inheritance. Results: Overall, 2122 out of 33,368 cases (6.4%) without lens opacity had keratoconus, while 20 out of 21 patients (95.2%) with peculiar lens opacity had definite keratoconus (P &lt; 0.001). Lens opacity was bilateral in 5 cases (24%), and keratoconus was bilateral in all 20 patients with lens opacity. Nine eyes out of thirty-six with a complete data record (25%) had severe keratoconus and underwent deep lamellar keratoplasty, while 11 (31%) had forme fruste keratoconus. Pedigrees were drawn for eight patients, most families of whom suggested an X-linked recessive inheritance. Conclusion: The present study was the first to investigate patients with a peculiar inferior feather-shape lens opacity accompanied by bilateral keratoconus, which was observed in 95% of the patients. This finding should raise awareness as to the possibility of diagnosing keratoconus in the eyes of the patients with these characteristics

Corneal Parameters in Healthy Subjects Assessed by Corvis ST

Purpose: To evaluate corneal biomechanics using Corvis ST in healthy eyes from Iranian keratorefractive surgery candidates. Methods: In this prospective consecutive observational case series, the intraocular pressure (IOP), central corneal thickness (CCT), and biomechanical properties of 1,304 eyes from 652 patients were evaluated using Corvis ST. Keratometric readings and manifest refraction were also recorded. Results: The mean (±SD) age of participants was 28 ± 5 years, and 31.7% were male. The mean spherical equivalent refraction was –3.50 ± 1.57 diopters (D), the mean IOP was 16.8 ± 2.9 mmHg, and the mean CCT was 531 ± 31 μm for the right eye. The respective means (±SD) corneal biomechanical parameters of the right eye were as follows: first applanation time: 7.36 ± 0.39 milliseconds (ms); first applanation length: 1.82 ± 0.22 mm; velocity in: 0.12 ± 0.04 m/s; second applanation time: 20.13 ± 0.48 ms; second applanation length: 1.34 ± 0.55 mm; velocity out: –0.67 ± 0.17 m/s; total time: 16.84 ± 0.64 ms; deformation amplitude: 1.05 ± 0.10 mm; peak distance: 4.60 ± 1.01 mm; and concave radius of curvature: 7.35 ± 1.39 mm. In the linear regression analysis, IOP exhibited a statistically significant association with the first and second applanation times, total time, velocity in, peak distance, deformation amplitude, and concave radius of curvature. Conclusion: Our study results can be used as a reference for the interpretation of Corvis ST parameters in healthy refractive surgery candidates in the Iranian population. Our results confirmed that IOP is a major determinant of Corvis parameters

In vitro evaluation of actively targetable superparamagnetic nanoparticles to the folate receptor positive cancer cells

Engineering of a physiologically compatible, stable and targetable SPIONs-CA-FA formulation was reported. Initially fabricated superparamagnetic iron oxide nanoparticles (SPIONs) were coated with citric acid (CA) to hamper agglomeration as well as to ameliorate biocompatibility. Folic acid (FA) as a targeting agent was then conjugated to the citric acid coated SPIONs (SPIONs-CA) for targeting the specific receptors expressed on the FAR + cancer cells. Physiochemical characterizations were then performed to assure required properties like stability, size, phase purity, surface morphology, chemical integrity and magnetic properties. In vitro evaluations (MTT assay) were performed on HeLa, HSF 1184, MDA-MB-468 and MDA-MB-231cell lines to ensure the biocompatibility of SPIONs-CA-FA. There were no morphological changes and lysis in contact with erythrocytes recorded for SPIONs-CA-FA and SPIONs-CA. High level of SPIONs-CA-FA binding to FAR + cell lines was assured via qualitative and quantitative in vitro binding studies. Hence, SPIONs-CA-FA was introduced as a promising tool for biomedical applications like magnetic hyperthermia and drug delivery. The in vitro findings presented in this study need to be compared with those of in vivo studies

Radioimmunoscintigraphy of Breast Tumor Xenografts in Mouse Model by 99mTc Direct Radiolabeling of a Monoclonal Antibody PR81

Introduction: The radioimmunoscintigraphy (RIS) has found widespread clinical applications in  tumor  diagnosis.  Human  epithelial  mucin,  MUC1,  is  commonly  over  expressed  in  adenocarcinoma including 80% of breast cancers and represents a useful target for RIS. The PR81  is  a  new  murine  anti-MUC1  monoclonal  antibody  that  was  found  to  react  with  the  membrane  extracts of several human breast cancerous tissues and the cell surface of some MUC1 positive  cell lines. In this study, a direct method which is very simple, rapid and efficient for the labeling  of this MAb with  99m Tc, particularly suitable for the development of a ‘kit’, was developed. The  quality  control  of  new  radiopharmaceutical  and  immunoscintigraphy  studies  in  BALB/c  mice  bearing breast tumor xenografts were also performed.  Materials and Methods: The Ab reduction was performed with 2-mercaptoethanol (2-ME) at a  molar  ratio  of  2000:1  (2-ME:MAb)  and  reduced  Ab  was  labeled  with  99m Tc  via  methylene  diphosphonate (MDP) as a transchelator. The labeling efficiency was determined by ITLC. The  amount  of  radiocolloids  was  measured  by  cellulose  nitrate  electrophoresis.  The  stability  of  the  labeled product was checked in fresh human serum by gel filtration chromatography (FPLC) over  24 hrs. The integrity of the labeled MAb was checked by the means of SDS-PAGE. Cell-binding  assay  was  used  to  test  the  binding  ability  of  99m Tc-PR81  to  MCF7  cells.  Biodistribution  was  studied in normal BALB/c mice at 4 and 24 hrs post-injection. The tumor imaging was performed  in female BALB/c mice with breast tumor xenografts 24 hrs after the new complex injection.  Results:  The  labeling  efficiency  was  94.2%±2.3  and  radiocolloids  were  2.5%±1.7.  In  vitro  stability  was  70%±5.7  in  fresh  human  serum  over  24  hrs.  There  was  no  significant  Ab  fragmentation due to the labeling procedure. Both the labeled and unlabeled PR81 were able to  compete for binding to MCF7 cells. The biodistribution studies in normal BALB/c mice showed  that  there  was  no  important  accumulation  in  any  organ.  The  immunoscintigraphy  studies  demonstrated definite localization of the preparation at the site of tumors with high sensitivity.  Discussion and Conclusion: The results show that by using the Schwarz method of radiolabeling  MAb PR81, a labeling yield higher than 90% with high stability of the complex in human serum  can be obtained. These findings demonstrated that the new radiopharmaceutical can be considered  as a promising candidate for imaging of human breast cancer